Daytrana

Daytrana

Daytrana (formerly known as MethylPatch) is a medicinal patch marketed by Shire Pharmaceuticals and developed under contract by Noven Pharmaceuticals that was approved in June 2007. In the literature, Daytrana is most commonly referred to as Methylphenidate Transdermal System (MTS).

Daytrana is approved by the U.S. Food and Drug Administration (FDA) as a once daily treatment of pediatric patients—ages 6 to 12—with Attention Deficit Hyperactivity Disorder. However, off-label prescriptions in older patients are not uncommon. It is mainly prescribed as a second-line treatment for ADHD when traditional oral forms are not well-tolerated or if patients have difficulty with compliance.

Noven's original FDA submission of MethylPatch indicated that it should be used for 12 hours; when the FDA rejected the submission they requested evidence that a shorter time period was safe and effective; Noven provided such evidence and Daytrana was approved for the aforementioned indication over a 9 hour period.[1]

Transdermal versus oral administration

Unlike with transdermal administration, orally administered methylphenidate is subject to first-pass metabolism, by which the levo-isomer is extensively metabolized. By circumvention of this first-pass metabolism the relative concentrations of l-threo-methylphenidate are much higher with transdermal administration (50-60 % of those of dexmethylphenidate instead of about 14-27 %). [2] [3] Because the d-enantiomer by far is pharmacologically the most active one, this is of limited importance.

Footnotes

  1. ^ http://www.fda.gov/ohrms/dockets/AC/05/briefing/2005-4195B1_01_04-Noven-Appendix-3.pdf
  2. ^ Heal DJ, Pierce DM (2006). "Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system". CNS Drugs 20 (9): 713–738 (Page:730). doi:10.2165/00023210-200620090-00002. PMID 16953648. 
  3. ^ Anderson Vanessa R., Lesley J. Scott (2006). "Methylphenidate Transdermal System In Attention-Deficit Hyperactivity Disorder in Children". Drugs 66 (8): 1117–1126. PMID 16789796. 

External links

v · d · eRoutes of administration / Dosage forms
Oral
Buccal / Sublabial / Sublingual
FlattenedRoundPills.jpg
Hexaaquatitanium(III)-solution.jpg
Inhaler.jpg
Glycerin suppositories.jpg
SPF15SunBlock.JPG
Syringe2.jpg
Nuvola apps filetypes red.svg
Ocular / Otologic / Nasal
Urogenital
Rectal (enteral)
Dermal
Injection / Infusion
(into tissue/blood)
  • Intracavernous
  • Intravitreal
  • Intra-articular or intrasynovial injection
  • Transscleral
Additional explanation:
Mucous membranes are used by the human body to absorb the dosage for all routes of administration, except for "Dermal" and "Injection/Infusion".
Administration routes can also be grouped as Topical (local effect) or Systemic (defined as Enteral = Digestive tract/Rectal, or Parenteral = All other routes).
v · d · eRoutes of administration by organ system
Gastrointestinal
Oral • Buccal • Sublabial • Sublingual • Rectal
Respiratory system
Pulmonary • Nasal
Visual system / Auditory system
Ocular (Ocular-topical / Intravitreal / Transscleral) • Otologic (Oto-topical)
Reproductive system
Intracavernous • Intravaginal • Intrauterine (Extra-amniotic)
Urinary system
Intravesical
Peritoneum
Central nervous system
Intracerebral • Intrathecal • Epidural
Circulatory system
Musculoskeletal system
Skin
Epicutaneous • Intradermal • Subcutaneous


Stub icon This medical treatment-related article is a stub. You can help Wikipedia by expanding it.